


GAS TRANSPORT AND pH REGULATION

James Baggott



- 25.1 INTRODUCTION TO GAS TRANSPORT 1026
- 25.2 NEED FOR A CARRIER OF OXYGEN IN BLOOD 1026
Respiratory System Anatomy Affects Blood Gas Concentration 1027
A Physiological Oxygen Carrier Must Have Unusual Properties 1027
The Steep Part of the Curve Lies in the Physiological Range 1028
- 25.3 HEMOGLOBIN AND ALLOSTERISM: EFFECT OF 2,3-BISPHOSPHOGLYCERATE 1029
- 25.4 OTHER HEMOGLOBINS 1030
- 25.5 PHYSICAL FACTORS THAT AFFECT OXYGEN BINDING 1031
High Temperature Weakens Hemoglobin's Oxygen Affinity 1031
Low pH Weakens Hemoglobin's Oxygen Affinity 1031
- 25.6 CARBON DIOXIDE TRANSPORT 1031
Blood CO_2 Is Present in Three Major Forms 1031
Bicarbonate Formation 1032
Carbaminohemoglobin Formation 1032
Two Processes Regulate $[\text{H}^+]$ Derived from CO_2
Transport 1033
Buffering 1033
Isohydric Mechanism 1034
 HCO_3^- Distribution Between Plasma and Erythrocytes 1035
- 25.7 INTERRELATIONSHIPS AMONG HEMOGLOBIN, OXYGEN, CARBON DIOXIDE, HYDROGEN ION, AND 2,3-BISPHOSPHOGLYCERATE 1036
- 25.8 INTRODUCTION TO pH REGULATION 1036
- 25.9 BUFFER SYSTEMS OF PLASMA, INTERSTITIAL FLUID, AND CELLS 1036
- 25.10 THE CARBON DIOXIDE-BICARBONATE BUFFER SYSTEM 1038
The Chemistry of the System 1038
The Equilibrium Expression Involves an Anhydride Instead of an Acid 1038
- The Carbon Dioxide-Bicarbonate Buffer System Is an Open System 1039
Graphical Representation: The pH-Bicarbonate Diagram 1040
- 25.11 ACID-BASE BALANCE AND ITS MAINTENANCE 1041
The Kidney Plays a Critical Role in Acid-Base Balance 1043
Urine Formation Occurs Primarily in the Nephron 1043
The Three Fates of Excreted H^+ 1043
Total Acidity of the Urine 1045
- 25.12 COMPENSATORY MECHANISMS 1046
Principles of Compensation 1046
The Three States of Compensation Defined 1046
Specific Compensatory Processes 1047
Respiratory Acidosis 1047
Respiratory Alkalosis 1047
Metabolic Acidosis 1048
Metabolic Alkalosis 1048
- 25.13 ALTERNATIVE MEASURES OF ACID-BASE IMBALANCE 1049
- 25.14 THE SIGNIFICANCE OF Na^+ AND Cl^- IN ACID-BASE IMBALANCE 1050
- BIBLIOGRAPHY 1052
- QUESTIONS AND ANSWERS 1052
- CLINICAL CORRELATIONS
- 25.1 Diaspirin Hemoglobin 1026
- 25.2 Cyanosis 1028
- 25.3 Chemically Modified Hemoglobins: Methemoglobin and Sulfhemoglobin 1030
- 25.4 Hemoglobins with Abnormal Oxygen Affinity 1032
- 25.5 The Case of the Variable Constant 1039
- 25.6 The Role of Bone in Acid-Base Homeostasis 1042
- 25.7 Acute Respiratory Alkalosis 1047
- 25.8 Chronic Respiratory Acidosis 1048
- 25.9 Salicylate Poisoning 1049
- 25.10 Evaluation of Clinical Acid-Base Data 1051
- 25.11 Metabolic Alkalosis 1052

25.1 INTRODUCTION TO GAS TRANSPORT

Large organisms, especially terrestrial ones, require a relatively tough, impermeable outer covering to help shield them from dust, twigs, nonisotonic fluids like rain and seawater, and other elements in the environment that might be harmful to living cells. One of the consequences of being large and having an impermeable covering is that individual cells of the organism cannot exchange gases directly with the atmosphere. Instead there must exist a specialized exchange surface, such as a lung or a gill, and a system to circulate the gases (and other materials, such as nutrients and waste products) in a manner that will meet the needs of every living cell in the body.

The existence of a system for the transport of gases from the atmosphere to cells deep within the body is not merely necessary, it has definite advantages. Oxygen is a good oxidizing agent, and at its partial pressure in the atmosphere, about 160 mmHg or 21.3 kPa, it would oxidize and inactivate many components of the cells, such as essential sulfhydryl groups of enzymes. By the time O_2 gets through the transport system of the body its partial pressure is reduced to a much less damaging 20 mmHg (2.67 kPa) or less. In contrast, CO_2 is relatively concentrated in the body and becomes diluted in transit to the atmosphere. In the tissues, where it is produced, its partial pressure is 46 mmHg (6.13 kPa) or more. In the lungs it is 40 mmHg (5.33 kPa), and in the atmosphere only 0.2 mmHg (0.03 kPa), less abundant than the rare gas, argon. Its relatively high concentration in the body permits it to be used as one component of a physiologically important buffering system, a system that is particularly useful because, upon demand, the concentration of CO_2 in the extracellular fluid can be varied over a rather wide range. This is discussed in more detail later in the chapter.

Oxygen and CO_2 are carried between the lungs and the other tissues by the blood. In the blood some of each gas is present in simple physical solution, but mostly each is involved in some sort of interaction with hemoglobin, the major protein of the red blood cell. There is a reciprocal relation between hemoglobin's affinity for O_2 and CO_2 , so that the relatively high level of O_2 in the lungs aids the release of CO_2 , which is to be expired, and the high CO_2 level in other tissues aids the release of O_2 for their use. Thus a description of the physiological transport of O_2 and CO_2 is the story of the interaction of these two compounds with hemoglobin.

CLINICAL CORRELATION 25.1

Diaspirin Hemoglobin

Shock is a condition of inadequate tissue perfusion due, for example, to loss of blood. Hemorrhagic shock is a major cause of death following trauma. Rapid blood transfusion can be life-saving, but cross-matching must be done before transfusing blood, and transfusion is associated with a significant risk of disease. In addition, blood (or blood of the correct type) may be in short supply under certain circumstances. Hence there is considerable interest in developing a safe, effective blood substitute.

Hemoglobin in plasma has a very short lifetime. It rapidly dissociates into $\alpha\beta$ dimers, which bind to the plasma protein haptoglobin, and are removed from circulation. Hemoglobin can be specifically cross-linked with bis(3,5-dibromosalicyl) fumarate at the Lys 99 of the α chains; the product is called diaspirin cross-linked hemoglobin (DCLHb). DCLHb has a longer lifetime in plasma than hemoglobin, and its lifetime can be extended still further by polymerizing the DCLHb. DCLHb has performed well as a blood replacement in experimental animals, and the possibility of using it in humans is being pursued.

25.2 NEED FOR A CARRIER OF OXYGEN IN BLOOD

An O_2 carrier is needed in blood because O_2 is not soluble enough in blood plasma to meet the body's needs. At 38°C, 1 L of plasma dissolves only 2.3 mL of O_2 . Whole blood, because of its **hemoglobin**, has a much greater oxygen capacity (see Clin. Corr. 25.1). One liter of blood normally contains about 150 g of hemoglobin (contained within the erythrocytes), and each gram of hemoglobin can combine with 1.34 mL of O_2 . Thus the hemoglobin in 1 L of blood can carry 200 mL of O_2 , 87 times as much as plasma alone would carry. Without an O_2 carrier, the blood would have to circulate 87 times as fast to provide the same amount of O_2 . As it is, the blood makes a complete circuit of the body in 60 s under resting conditions, and in the aorta it flows at the rate of about 18.6 m s⁻¹. An 87-fold faster flow would require a fabulous high-pressure pump, would produce tremendously turbulent flow and high shear forces in the plasma, would result in uncontrollable bleeding from wounds, and would not even allow the blood enough time in the lungs to take up O_2 . The availability of a carrier not only permits us to avoid these impracticalities, but also gives us a way of controlling oxygen delivery, since the O_2 affinity of the carrier is responsive to changing physiological conditions.

Respiratory System Anatomy Affects Blood Gas Concentration

The respiratory system includes the trachea, in the neck, which bifurcates in the thorax into right and left bronchi, as shown schematically in Figure 25.1. The bronchi continue to bifurcate into smaller and smaller passages, ending in tiny bronchioles, which open into microscopic gas-filled sacs called alveoli. It is in the alveoli that gas exchange takes place with the alveolar capillary blood.

As we inhale and exhale, the alveoli do not appreciably change in size. Rather, it is the airways that change in length and diameter as the air is pumped in and out of the lungs. Gas exchange between the airways and the alveoli proceeds simply by diffusion. These anatomical and physiological facts have two important consequences. In the first place, since the alveoli are at the ends of long tubes that constitute a large dead space, and the gases in the alveoli are not completely replaced by fresh air with each breath, the gas composition of the alveolar air differs from that of the atmosphere, as shown in Table 25.1. Oxygen concentration is lower in the alveoli because it is removed from the blood. Carbon dioxide concentration is higher because it is added. Since we do not usually breathe air that is saturated with water vapor at 38°C, water vapor is generally added in the airways. The concentration of nitrogen is lower in the alveoli, not because it is taken up by the body, but simply because it is diluted by the CO₂ and water vapor.

A second consequence of the existence of alveoli of essentially constant size is that the blood that flows through the pulmonary capillaries during expiration, as well as the blood that flows through during inspiration, can exchange gases. This would not be possible if the alveoli collapsed during expiration and contained no gases, in which case the composition of the blood gases would fluctuate widely, depending on whether the blood passed through the lungs during an inspiratory or expiratory phase of the breathing cycle.




FIGURE 25.1
Diagram showing the respiratory tract.

Physiological Oxygen Carrier Must Have Unusual Properties

We have seen that an O₂ carrier is necessary. Clearly this carrier would have to be able to bind oxygen at an O₂ tension of about 100 mmHg (13.3 kPa), the partial pressure of oxygen in the alveoli. The carrier must also be able to release O₂ to the extrapulmonary tissues. The O₂ tension in the capillary bed of an active muscle is about 20 mmHg (2.67 kPa). In resting muscle it is higher, but during extreme activity it is lower. These O₂ tensions represent the usual limits within which an oxygen carrier must work. An efficient carrier would be nearly fully saturated in the lungs but should be able to give up most of this to a working muscle.

Let us first see whether a carrier that binds O₂ in a simple equilibrium is presented by




TABLE 25.1 Partial Pressures of Important Gases Given in Millimeters of Hg (kPa)

Gas	In the Atmosphere		In the Alveoli of the Lungs	
	mmHg	kPa	mmHg	kPa
O ₂	159	21.2	100	13.3
N ₂	601	80.1	573	76.4
CO ₂	0.2	0.027	40	5.33
H ₂ O	0	0	47	6.27
Total	760	101	760	101




FIGURE 25.2
Oxygen saturation curves for two hypothetical oxygen carriers and for hemoglobin.

Curve A: Hypothetical carrier with hyperbolic saturation curve (a simple carrier), 90% saturated in the lungs and 66% saturated at the partial pressure found in interstitial fluid.

Curve B: Hypothetical carrier with hyperbolic saturation curve (another simple carrier), 56% saturated in the lungs and 20% saturated at the partial pressure found in interstitial fluid. Dashed curve: Hemoglobin in whole blood.

CLINICAL CORRELATION 25.2

Cyanosis

Cyanosis is a condition in which a patient's skin or mucous membrane appears gray or (in severe cases) purple-magenta. It is due to an abnormally high concentration of deoxyhemoglobin below the surface, which is responsible for the observed color. The familiar blue of superficial veins is due to their deoxyhemoglobin content and is a normal manifestation of this color effect.

Cyanosis is most commonly caused by diseases of the cardiac or pulmonary systems, resulting in inadequate oxygenation of the blood. It can also be caused by certain hemoglobin abnormalities. Severely anemic individuals cannot become cyanotic; they do not have enough hemoglobin in their blood for the characteristic color of its deoxy form to be apparent.

Albert, R. K. Approach to the patient with cyanosis and/or hypoxemia. In: W. N. Kelley (Ed.), *Textbook of Internal Medicine*. Philadelphia: Lippincott, 1989, pp. 2041-2044.

would be satisfactory. For this type of carrier the dissociation constant would be given by the simple expression

$$K_d = \frac{[\text{oxygen}][\text{carrier}]}{[\text{oxygen} \cdot \text{carrier}]}$$

and the saturation curve would be a **rectangular hyperbola**. This mode would be valid even for a carrier with several oxygen-binding sites per molecule which we know is the case for hemoglobin, as long as each site were independent and not influenced by the presence or absence of O_2 at adjacent sites.

If such a carrier had a dissociation constant that permitted 90% saturation in the lungs, then, as shown in Figure 25.2, curve A, at a partial pressure of 27 mmHg (2.67 kPa) it would still be 66% saturated and would have delivered only 24% of its O_2 load. This would not be very efficient.

What about some other simple carrier, one that bound O_2 less tightly and therefore released most of it at low partial pressure, so that the carrier was, say only 20% saturated at 20 mmHg (2.67 kPa)? Again, as shown in Figure 25.2 curve B, it would be relatively inefficient; in the lungs this carrier could fill only 56% of its maximum O_2 capacity and would deliver only 36% of what it could carry. It appears then that the mere fivefold change in O_2 tension between the lungs and the unloading site is not compatible with efficient operation of a simple carrier. Simple carriers are not sensitive enough to respond massively to a signal as small as a fivefold change.

Figure 25.2 also shows the oxygen-binding curve of hemoglobin in normal blood. The curve is **sigmoid**, not hyperbolic, and it cannot be described by a simple equilibrium expression. Hemoglobin, however, is a very good physiological O_2 carrier. It is 98% saturated in the lungs and only about 33% saturated in the working muscle. Under these conditions it delivers about 65% of the O_2 it can carry.

It can be seen in Figure 25.2 that hemoglobin is 50% saturated with O_2 at a partial pressure of 27 mmHg (3.60 kPa). The partial pressure corresponding to 50% saturation is called the P_{50} . The term P_{50} is the most common way of expressing hemoglobin's O_2 affinity. By analogy with K_m for enzymes, a relatively high P_{50} corresponds to a relatively low O_2 affinity.

The Steep Part of the Curve Lies in the Physiological Range

Note that the steep part of hemoglobin's saturation curve lies in the range of O_2 tensions that prevail in the extrapulmonary tissues. This means that relatively small decreases in oxygen tension in these tissues will result in large increases in O_2 delivery, this effect becoming more pronounced as the partial pressure of O_2 diminishes within the physiological range. Furthermore, small shifts of the curve to the left or right will also strongly influence O_2 delivery. In Sections 25.3, 25.5, and 25.6 we see how physiological signals effect such shifts and result in enhanced delivery under conditions of increased O_2 demand. Small decreases of O_2 tension in the lungs, however, such as occur at moderately high altitudes, do not seriously compromise hemoglobin's ability to bind oxygen. This will be true as long as the alveolar partial pressure of O_2 remains in a range that corresponds to the relatively flat region of hemoglobin's O_2 dissociation curve (see Clin. Corr. 25.2).

Finally, we can see from Figure 25.2 that the binding of oxygen by hemoglobin is cooperative. At very low O_2 tension the hemoglobin curve tends to follow the hyperbolic curve, which represents relatively weak O_2 binding, but at higher tensions it actually rises above the hyperbolic curve that represents tight binding. Thus hemoglobin binds O_2 weakly at low oxygen tension and tightly at high tension. The binding of the first O_2 to each hemoglobin molecule enhances the binding of subsequent O_2 molecules.

Hemoglobin's ability to bind O_2 cooperatively is reflected in its **Hill coefficient**, which has a value of about 2.7. (The Hill equation is derived and interred on p. 119.) Since the maximum value of the Hill coefficient for a system in equilibrium is equal to the number of cooperating binding sites, a value of 2.7 means that hemoglobin, with its four oxygen-binding sites, is more cooperative than would be possible for a system with only two cooperating binding sites, but it is not as cooperative as it could be.

HEMOGLOBIN AND ALLOSTERISM: EFFECT OF 2,3-BISPHOSPHOGLYCERATE

Hemoglobin's binding of O_2 was the original example of a **homotropic effect** (cooperativity and allosterism are discussed in Chapter 4), but hemoglobin also exhibits a **heterotropic effect** of great physiological significance. This involves interaction with **2,3-bisphosphoglycerate (BPG)** (Figure 25.3), which is directly related to the glycolytic intermediate, 1,3-bisphosphoglycerate, from which it is biosynthesized.

It had been known for many years that hemoglobin in the red cell bound O_2 less tightly than purified hemoglobin could (Figure 25.4). It had also been known that the red cell contained high levels of BPG, nearly equimolar with hemoglobin. Finally, the appropriate experiment was done to demonstrate relationships between these two facts. It was shown that the addition of purified hemoglobin produced a shift to the right of its oxygen-binding curve, bringing it into congruence with the curve observed for whole blood. Organic polyphosphates, such as ATP and inositol pentaphosphate, also have this effect. Inositol pentaphosphate is the physiological effector in birds, and ATP replaces BPG, and ATP plays a similar role in some fish.

Perutz's model of allosterism explains heterotropic interaction. Applying it to hemoglobin, in the deoxy conformation (the **T state**) a cavity is large enough to admit BPG exists between the β chains of hemoglobin. This cavity is lined with positively charged groups and firmly binds one molecule of the negatively charged BPG. In the oxy conformation (the **R state**) this cavity is smaller, and it no longer accommodates BPG as easily. The result is that the binding of BPG to oxyhemoglobin is much weaker. Since BPG binds preferentially to the T state, the presence of BPG shifts the R-T equilibrium in favor of the T state; the deoxyhemoglobin conformation is thus stabilized over the oxyhemoglobin conformation (Figure 25.5). For oxygen to overcome this and saturate hemoglobin, a higher concentration of oxygen is required. Oxygen in the lungs is sufficiently high under most conditions to saturate hemoglobin almost completely, even when BPG levels are high. The physiological effect of BPG can, therefore, be expected to be upon release of oxygen to the respiratory tissues, where O_2 tensions are low.

The significance of a high BPG concentration is that the efficiency of O_2 delivery is increased. Concentrations of BPG in the red cell rise in conditions associated with **tissue hypoxia**, such as various anemias, cardiopulmonary disease, and high altitude. These high levels of BPG enhance the formation of deoxyhemoglobin at low partial pressures of oxygen; hemoglobin then delivers its O_2 to the tissues. This effect can result in a substantial increase in the amount of O_2 delivered because the venous blood returning to the heart of a normal individual is (at rest) at least 60% saturated with O_2 . Much of this O_2 is released in the peripheral tissues if the BPG concentration rises.

The BPG mechanism works very well as a compensation for tissue hypoxia because the partial pressure of oxygen in the lungs remains high enough that oxygen loading in the lungs is not compromised. Since, however, BPG shifts the oxygen-binding curve to the right, the mechanism will not compensate for tissue hypoxia when the partial pressure of O_2 in the lungs falls too low. Then




FIGURE 25.3
2,3-Bisphosphoglycerate (BPG).




FIGURE 25.4
Oxygen dissociation curves for myoglobin, for hemoglobin that has been stripped of CO_2 and organic phosphates, and for whole red blood cells.

Data from Brenna, O., Luzzana, M., Pace, M., et al. *Adv. Exp. Biol. Med.* 28:19, 1972. Adapted from McGilvery, R. W. *Biochemistry: A Functional Approach*, 2nd ed. Philadelphia: Saunders, 1979, p. 236.





FIGURE 25.5
Schematic representation of equilibria among BPG, O_2 , and the T and R states of hemoglobin.

CLINICAL CORRELATION 25.3

Chemically Modified Hemoglobins: Methemoglobin and Sulfhemoglobin

Methemoglobin is a form of hemoglobin in which the iron is oxidized from the iron (II) state to the iron (III) state. A tendency for methemoglobin to be present in excess of its normal level of about 1% may be due to a hereditary defect of the globin chain or to exposure to oxidizing drugs or chemicals. Sulfhemoglobin is a species that forms when a sulfur atom is incorporated into the porphyrin ring of hemoglobin. Exposure to certain drugs or to soluble sulfides produces it. Sulfhemoglobin is green. Hemoglobin subunits containing these modified hemes do not bind oxygen, but they change the oxygen-binding characteristics of the normal subunits in hybrid hemoglobin molecules containing some normal subunits and one or more modified subunits. The accompanying figure shows the oxygen-binding curve of normal HbA, 15% methemoglobin and 12% sulfhemoglobin. The presence of methemoglobin shifts the curve to the left, impairing the delivery of the decreased amount of bound oxygen. In contrast, the sulfhemoglobin curve is shifted to the right, a BPG-like effect. As a result, oxygen delivery is enhanced, partially compensating for the inability of the sulfur-modified hemes to bind oxygen.



Oxygenation curves of unmodified hemoglobin A (squares) of a 15% oxidized hemolysate (circles) and of a hemolysate containing 12% sulfhemoglobin (triangles) in 0.1 M phosphate, pH 7.35, at 20°C.

Data from Park, C. M., and Nagel, R. L., N. Engl. J. Med. 310:1579, 1984.

the increased efficiency of O₂ unloading to the tissues is counterbalanced by a decrease in the efficiency of loading in the lungs. This may be a factor in determining the maximum altitude at which people choose to establish permanent dwellings, which is about 18,000 ft (~5500 m). There is evidence that a better adaptation to extremely low ambient partial pressures of O₂ would be a shift of the curve to the left.

25.4 OTHER HEMOGLOBINS

Although hemoglobin A is the major form of hemoglobin in adults and in children over seven months of age, accounting for about 90% of their total hemoglobin, it is not the only normal hemoglobin species. Normal adults also have 2–3% of **hemoglobin A₂**, which is composed of two α chains like those in hemoglobin A and two δ chains. It is represented as $\alpha_2\delta_2$. The δ chains differ in amino acid sequence from the β chains and are under independent genetic control. Hemoglobin A₂ does not appear to be important in normal individuals.

Several species of modified hemoglobin A also occur normally. These are designated A_{1a1}, A_{1a2}, A_{1b}, and A_{1c}. They are adducts of hemoglobin with various sugars, such as glucose, glucose 6-phosphate, and fructose 1,6-bisphosphate. The quantitatively most significant is **hemoglobin A_{1c}**, formed by covalent binding of a glucose residue to the N terminal of the β chain at a rate that depends on the concentration of glucose. As a result, hemoglobin A_{1c} forms more rapidly in uncontrolled diabetics and can comprise up to 12% of their total hemoglobin. Hemoglobin A_{1c} or total glycosylated hemoglobin levels are a useful measure of how well diabetes has been controlled during the days and weeks before the measurement is taken; measurement of blood glucose only indicates how well diabetes is under control when the blood sample is taken. Chemical modification of hemoglobin A can also occur from interaction with drugs or environmental pollutants (see Clin. Corr. 25.3).

Fetal hemoglobin, **hemoglobin F**, is the major hemoglobin in newborn infants. It contains two γ chains in place of the β chains and is represented as $\alpha_2\gamma_2$. Shortly before birth γ -chain synthesis diminishes and β -chain synthesis is initiated, and by the age of seven months well over 90% of the infant's hemoglobin is hemoglobin A.

Hemoglobin F is adapted to the environment of the fetus, who gets oxygen from maternal blood, a source that is far poorer than the atmosphere. To compete with the maternal hemoglobin for O₂, fetal hemoglobin must bind O₂ more tightly; its oxygen-binding curve is thus shifted to the left relative to hemoglobin A. This is accomplished through a difference in the influence of BPG upon the maternal and fetal hemoglobins. In hemoglobin F two of the groups that line the BPG-binding cavity have neutral side chains instead of the positively charged ones that occur in hemoglobin A. Consequently, hemoglobin F binds BPG less tightly and thus binds oxygen more tightly than hemoglobin A does. Also, about 15–20% of the hemoglobin F is acetylated at the N terminals; this is referred to as hemoglobin F₁. Hemoglobin F₁ does not bind BPG, and its affinity for oxygen is not affected at all by BPG. The postnatal change from hemoglobin F to hemoglobin A, combined with a rise in red cell BPG that peaks three months after birth, results in a gradual shift to the right of the infant's oxygen-binding curve (Figure 25.6). The result is greater delivery of oxygen to the tissues at this age than at birth, in spite of a 30% decrease in the infant's total hemoglobin concentration.

In many inherited anomalies of hemoglobin synthesis there is formation of a structurally abnormal hemoglobin; these are called **hemoglobinopathies**. They may involve the substitution of one amino acid in one type of polypeptide chain for some other amino acid or they may involve absence of one or more amino acid residues of a polypeptide chain. In some cases the change is clinically insignificant, but in others it causes serious disease (see Clin. Corr. 25.4).

5 PHYSICAL FACTORS THAT AFFECT OXYGEN BINDING

High Temperature Weakens Hemoglobin's Oxygen Affinity

Temperature has a significant effect on O₂ binding by hemoglobin (Figure 25.7). Below-normal temperatures the binding is tighter, resulting in a leftward shift of the curve; at higher temperatures the binding becomes weaker, and the curve is shifted to the right. The effect of elevated temperature is like that of high levels of BPG, in that both enhance unloading of oxygen. The temperature effect is physiologically useful, as it makes additional O₂ available to support the high metabolic rate found in fever or in exercising muscle with its elevated temperature. The relative insensitivity to temperature of O₂ binding at high partial pressure of oxygen minimizes compromise of O₂ uptake in the lungs under these conditions.


The tighter binding of O₂ that occurs in hypothermic conditions is not important in hypothermia induced for surgical purposes. Decreased O₂ utilization by the body and increased solubility of O₂ in plasma at lower temperatures, well as the increased solubility of CO₂, which acidifies the blood, compensate hemoglobin's diminished ability to release O₂.

Low pH Weakens Hemoglobin's Oxygen Affinity

Hydrogen ion concentration influences hemoglobin's O₂ binding. As shown in Figure 25.8, low pH shifts the curve to the right, enhancing O₂ delivery, whereas high pH shifts the curve to the left. It is customary to express O₂ binding by hemoglobin as a function of plasma pH because it is this value, not the pH within the erythrocyte, that is usually measured. Erythrocyte cell sap pH is lower than the plasma pH, but these two fluids are in equilibrium, and changes in one reflect changes in the other.

The influence of pH upon O₂ binding is physiologically significant, since a decrease in pH is often associated with increased oxygen demand. Increased metabolic rate increases production of carbon dioxide and, as in muscular exercise and hypoxic tissue, lactic acid. These acids produced by metabolism help release oxygen to support that metabolism.

The increase in acidity of hemoglobin as it binds O₂ is known as the **Bohr effect**; an equivalent statement is that the Bohr effect is the increase in basicity of hemoglobin as it releases oxygen. The effect may be expressed by the equation



This equation gives the same information as Figure 25.8—that increases in hydrogen ion concentration favor formation of free oxygen from oxyhemoglobin, and conversely, that oxygenation of hemoglobin lowers the pH of the solution.

6 CARBON DIOXIDE TRANSPORT

The carbon dioxide we produce is excreted by the lungs, to which it is transported by the blood. Carbon dioxide transport is closely tied to hemoglobin and to the problem of maintaining a constant pH in the blood, a problem that will be discussed subsequently.

Carbon Dioxide Is Present in Three Major Forms

Carbon dioxide is present in the blood in three major forms, as dissolved CO₂, HCO₃⁻ (formed by ionization of H₂CO₃ produced when CO₂ reacts with H₂O), and as carbaminohemoglobin (formed when CO₂ reacts with amino groups of hemoglobin). Each of these is present both in arterial blood and in venous blood




FIGURE 25.6 Oxygen dissociation curves after birth. Adapted from Oski, F. A., and Delivoria-Papadopoulos, M. J. *Pediatr.* 77:941, 1970.




FIGURE 25.7 Oxygen dissociation curve for whole blood at various temperatures. From Lambertson, C. J. In: P. Bard (Ed.), *Medical Physiology, 11th ed.* St. Louis, MO: Mosby, 1961, p. 596.




FIGURE 25.8 Oxygen dissociation curve for whole blood at various values of plasma pH. Adapted from Lambertson, C. J. In: P. Bard (Ed.), *Medical Physiology, 11th ed.* St. Louis, MO: Mosby, 1961, p. 596.


CLINICAL CORRELATION 25.4

Hemoglobins with Abnormal Oxygen Affinity

Some abnormal hemoglobins have an altered affinity for oxygen. If oxygen affinity is increased (P_{50} decreased), oxygen delivery to the tissues will be diminished unless some sort of compensation occurs. Typically, the body responds by producing more erythrocytes (polycythemia) and more hemoglobin. Hb Rainier is an abnormal hemoglobin in which the P_{50} is 12.9 mmHg, far below the normal value of 27 mmHg.

In the accompanying figure the oxygen content in volume percent (mL of O_2 per 100 mL of blood) is plotted versus partial pressure of oxygen, both for normal blood (curve *a*) and for the blood of a patient with Hb Rainier (curve *b*). Obviously, the patient's blood carries more oxygen; this is because it contains 19.5 g of Hb per 100 mL instead of the usual 15 g per 100 mL.

Since the partial pressure of oxygen in mixed venous blood is about 40 mmHg, the volume of oxygen the blood of each individual can deliver may be obtained from the graph by subtracting the oxygen content of the blood at 40 mmHg from its oxygen content at 100 mmHg. As shown in the figure, the blood of the patient with Hb Rainier delivers nearly as much oxygen as normal blood does, although Hb Rainier delivers a significantly smaller fraction of the total amount it carries. Evidently, polycythemia is an effective compensation for this condition, at least in the resting state.




Oxygen content plotted against partial pressure of oxygen. (continued)

(see the top three lines of Table 25.2). Net transport to the lungs for excretion is represented by the concentration difference between arterial and venous blood, shown in the last column. Note that for each form of carbon dioxide the arterial-venous difference is only a small fraction of the total amount present; venous blood contains only about 10% more **total carbon dioxide** (total CO_2 is the sum of HCO_3^- , dissolved CO_2 , and carbaminohemoglobin) than arterial blood.

After carbon dioxide enters the bloodstream for transport, it generates hydrogen ions. Most come from formation of bicarbonate ion, which occurs in the following manner.

Bicarbonate Formation

Carbon dioxide enters the blood and diffuses into erythrocytes, whose membranes, like most biological membranes, are freely permeable to dissolved CO_2 . Within the erythrocytes most of the carbon dioxide is acted on by the intracellular enzyme, **carbonic anhydrase**, which catalyzes the reaction



This reaction proceeds in the absence of a catalyst, as is well known to all who drink carbonated beverages. Without the catalyst, however, it is too slow to meet the body's needs, taking over 100 s to reach equilibrium. Recall that at rest the blood makes a complete circuit of the body in 60 s. Carbonic anhydrase is a very active enzyme, having a turnover number of the order of 10^6 , and inside the erythrocytes the reaction reaches equilibrium within 1 s, less than the time spent by the blood in the capillary bed. The enzyme contains zinc and accounts in part for our dietary requirement for this metal.

The ionization of carbonic acid, $H_2CO_3 \rightleftharpoons H^+ + HCO_3^-$, is a rapid, spontaneous reaction. It produces equivalent amounts of H^+ and HCO_3^- . Since, as shown in the last column of line 2 in Table 25.2, 1.69 meq of bicarbonate was added to each liter of blood by this process, 1.69 meq of H^+ must also have been generated per liter of blood. Addition of this much acid, over 10^{-3} equiv of H^+ , to 1 L of water would give a final pH below 3. Since the pH of venous plasma averages 7.37, most of the H^+ generated during HCO_3^- production must be consumed by buffer action and/or other processes. This is discussed below.

Because of the compartmentalization of carbonic anhydrase, essentially all conversion of CO_2 to H_2CO_3 , and ultimately to HCO_3^- , occurs inside the erythrocyte. Negligible amounts of CO_2 react nonenzymatically in the plasma. Thus virtually all of the increase in HCO_3^- in venous as compared to arterial blood is generated in erythrocytes. Most of this diffuses into the plasma, so that venous plasma HCO_3^- is higher than the arterial, but the erythrocyte was the site of its formation.

Carbaminohemoglobin Formation

It has been observed that in the presence of carbonic anhydrase inhibitors, such as acetazolamide or cyanide, blood will still take up a certain amount of carbon dioxide rapidly. This is due to the reaction of carbon dioxide with amino groups of proteins within erythrocytes to form **carbamino groups** (Figure 25.9). Hemoglobin is quantitatively the most important protein involved in this reaction. Deoxyhemoglobin forms **carbamino hemoglobin** more readily than oxyhemoglobin. Oxygenation causes release of CO_2 in carbaminohemoglobin.

Carbaminohemoglobin formation occurs only with uncharged aliphatic amino groups, not with the charged form, $R-NH_3^+$. The pH within erythrocytes is normally about 7.2, somewhat more acidic than the plasma. Since protein amino groups have pK values well to the alkaline side of 7.2, they will be mostly in the charged (undissociated acid) form. Removal of some of the un-

charged form via carbamino group formation shifts the equilibrium, generating more uncharged amino groups and an equivalent amount of H⁺, as shown in Figure 25.10. Carbamation, like HCO₃⁻ formation, generates H⁺.

The N-terminal α-amino groups of proteins have pK values in the range of 7.6–8.4. The N terminals of hemoglobin's polypeptide chains are the principal sites of carbamation. If they are blocked chemically by reaction with cyanate, carbamino formation does not occur.

The N-terminal amino groups of the β-globin chains are part of the binding site for BPG. Since they cannot bind BPG and also form carbamino groups, a competition arises. Carbon dioxide diminishes the effect for BPG and, conversely, BPG diminishes the ability of hemoglobin to form carbaminohemoglobin. Ignorance of the latter interaction led to a major overestimation of the role of carbaminohemoglobin in carbon dioxide transport. Prior to the discovery of the BPG effect, careful measurements were made of the capacity of purified hemoglobin (no BPG present) to form carbaminohemoglobin. The results were assumed to be applicable to hemoglobin in the erythrocyte, leading to the erroneous conclusion that carbaminohemoglobin accounted for 25–30% or more of CO₂ transport. It now appears that 13–15% of CO₂ transport is via carbaminohemoglobin. Table 25.3 summarizes the contribution of each major form of blood carbon dioxide to overall CO₂ transport.

Curve *a* shows the oxygen dissociation curve of normal blood with a hemoglobin of 15 g dL⁻¹, P₅₀ 27 mmHg, n 2.8, at pH 7.4, 37°C. Curve *b* shows that of blood from a patient with Hb Rainier, having a hemoglobin of 19.5 g dL⁻¹, P₅₀ 12.9 mmHg, n 1.2, at the same pH and temperature. (1 mmHg ≈ 133.3 Pa.) On the right is shown the oxygen delivery. The compensatory polycythemia and hyperbolic curve of Hb Rainier result in practically normal arterial and venous oxygen tensions. Arrow indicates normal mixed venous oxygen tension.

From *Bellingham, A. J. Br. Med. Bull. 32:234, 1976.*

Two Processes Regulate [H⁺] Derived from CO₂ Transport

Buffering

Hemoglobin, besides carrying O₂ and CO₂ in the covalently bound form of a carbamino group, also plays the major role in handling the H⁺ produced in CO₂ transport. It does this by buffering and by the isohydric mechanism (discussed below). **Hemoglobin's buffering** power resides in its ionizable groups with pK values close to the intraerythrocyte pH. These include the four N-terminal amino groups and the imidazole side chains of the histidine residues. There are 38 histidines per hemoglobin tetramer; these provide most of hemoglobin's buffering ability.

In whole blood, buffering takes up about 60% of the acid generated in normal carbon dioxide transport. Although hemoglobin is by far the most important nonbicarbonate buffer in blood, the organic phosphates in the eryth-




FIGURE 25.9
Carbamino formation from a free amino group and carbon dioxide.




FIGURE 25.10
Dissociation of an ammonium ion to yield a free amino group and H⁺.

TABLE 25.2 Properties of Blood of Humans at Rest^a

	Arterial			Venous			A-V Difference		
	Serum	Cells	Blood	Serum	Cells	Blood	Serum	Cells	Blood
Hb carbamino groups (meq L ⁻¹ of blood)		1.13	1.13		1.42	1.42		+0.29	+0.29
HCO ₃ ⁻ (meq L ⁻¹ of blood)	13.83	5.73	19.56	14.84	6.41	21.25	+1.01	+0.68	+1.69
Dissolved CO ₂ (meq L ⁻¹ of blood)	0.71	0.48	1.19	0.82	0.56	1.38	+0.11	+0.08	+0.19
Total CO ₂ (meq L ⁻¹ of blood)	14.54	7.34	21.88	15.66	8.39	24.05	+1.12	+1.05	+2.17
Free O ₂ (mmol L ⁻¹ of blood)			0.10			0.04			-0.06
Bound O ₂ (mmol L ⁻¹ of blood)			8.60			6.01			-2.59
Total O ₂ (mmol L ⁻¹ of blood)			8.70			6.05			-2.65
P _{O₂} (mmHg)			88.0			37.2			-50.8
P _{CO₂} (mmHg)			41.0			47.5			+6.5
pH	7.40	7.19		7.37	7.17		-0.03	-0.02	
Volume (cc L ⁻¹ of blood)	551.7	448.3	1000	548.9	451.1	1000	-2.8	+2.8	0.0
H ₂ O (cc L ⁻¹ of blood)	517.5	322.8	840.0	514.7	325.6	840.0	-2.8	+2.8	0.0
Cl ⁻ (meq L ⁻¹ of blood)	57.71	24.30	82.01	56.84	25.17	82.01	-0.88	+0.88	0.0

Source: From Baggott, J. *Trends Biochem. Sci.* 3:N207, 1978, with permission of the publisher.

^a Hemoglobin, 9 mM; serum protein, 39.8 g L⁻¹ of blood; respiratory quotient, 0.82.

TABLE 25.3 Major Forms of Carbon Dioxide Transport

Species	Transport (%)
HCO ₃ ⁻	78
CO ₂ (dissolved)	9
Carbaminohemoglobin	13

TABLE 25.4 Processes Occurring at the N Terminals of the α Chains and β Chains of Hemoglobin

Process	N Terminals	
	α Chains	β Chains
Carbamino formation	Yes	Yes
BPG binding	No	Yes
H ⁺ binding in the Bohr effect	Yes	No


TABLE 25.5 Control of the Excess H⁺ Generated During Normal Carbon Dioxide Transport

Buffering	
By hemoglobin	50%
By other buffers	10%
Isohydric mechanism (hemoglobin)	40%


rocytes, the plasma proteins, and so on also make a significant contribution. Buffering by these compounds accounts for about 10% of the H⁺, leaving about 50% of acid control specifically attributable to buffering by hemoglobin. These buffer systems minimize the change in pH that occurs when acid or base is added but do not altogether prevent that change. A small difference in pH between arterial and venous blood is therefore observed.

Isohydric Mechanism


The remainder of the H⁺ arising from carbon dioxide is taken up by hemoglobin, but not by buffering. Recall that when hemoglobin becomes oxygenated it becomes a stronger acid and releases H⁺ (the Bohr effect). In the capillaries, where O₂ is released, the opposite occurs:



Simultaneously, CO₂ enters the capillaries and is hydrated:




Addition of these two equations gives



revealing that to some extent this system can take up H⁺ arising from CO₂, and can do so without a change in H⁺ concentration (i.e., with no change in pH). Hemoglobin's ability to do this, through the operation of the Bohr effect, is referred to as the **isohydric carriage of CO₂**. As already pointed out, there is a small A-V difference in plasma pH. This is because the isohydric mechanism cannot handle all the acid generated during normal CO₂ transport; if it could, no such difference would occur. Figure 25.11 is a schematic representation of

FIGURE 25.11 Schematic representation of oxygen transport and the isohydric carriage of CO₂ by hemoglobin.

In the lungs (left) O₂ from the atmosphere reacts with deoxyhemoglobin, forming oxyhemoglobin and H⁺. The H⁺ combines with the HCO₃⁻ to form H₂O and CO₂. The CO₂ is exhaled. Oxyhemoglobin is carried to extrapulmonary tissues (right), where it dissociates in response to low P_{O₂}. The O₂ is used by metabolic processes, and CO₂ is produced. CO₂ combines with H₂O to give HCO₃⁻ and H⁺. H⁺ can then react with deoxyhemoglobin to give HHb, which returns to the lungs, and the cycle repeats.



O₂ transport and the isohydric mechanism, showing what happens in the lungs and in the other tissues.

Estimates of the importance of the isohydric mechanism in handling normal respiratory acid production have changed upward and downward over the years. The older, erroneous estimates arose out of a lack of knowledge of the multiple interactions in which hemoglobin participates. The earliest experiments, titrations of purified oxyhemoglobin and purified deoxyhemoglobin, revealed that oxygenation of hemoglobin resulted in release of an average of 0.7 H⁺ for every O₂ bound. This figure still appears in textbooks, and much is made of it. Authors point out that with a Bohr effect of this magnitude the isohydric mechanism alone could handle all of the acid produced by the metabolic oxidation of fat (RQ of fat is 0.7), and buffering would be unnecessary. Unfortunately, the experimental basis for this interpretation is physiologically unrealistic; the titrations were done in the total absence of carbon dioxide, which we now know binds to some of the Bohr groups, forming carbamino groups and diminishing the effect. When later experiments were carried out in the presence of physiological amounts of carbon dioxide, there was a drastic diminution of the Bohr effect, so much so that at pH 7.45 the isohydric mechanism was able to handle only the amount of acid arising from carbamino group formation. This work, however, was done prior to our appreciation of the competition between BPG and CO₂ for the same region of the hemoglobin molecule (see Table 25.4). Finally, in 1971, careful titrations of whole blood under presumably physiological conditions were carried out, yielding a value of 0.31 H⁺ released per O₂ bound. This value is the basis of the present assertion that the isohydric mechanism accounts for about 40% of the H⁺ generated during normal carbon dioxide transport. The quantitative contributions of various mechanisms to the handling of H⁺ arising during carbon dioxide transport are summarized in Table 25.5. The major role of hemoglobin in handling this acid is obvious.


HCO₃⁻ Distribution Between Plasma and Erythrocytes

We have seen that essentially all of HCO₃⁻ formation is intracellular, catalyzed by carbonic anhydrase, and that the vast bulk of the H⁺ generated by CO₂ is handled within the erythrocyte. These two observations bear upon the final distribution of HCO₃⁻ between plasma and the erythrocyte.

Intracellular formation of HCO₃⁻ increases its intracellular concentration. Since HCO₃⁻ and Cl⁻ exchange freely across the erythrocyte membrane, HCO₃⁻ will diffuse out of the erythrocyte, increasing the plasma HCO₃⁻ concentration. Electrical neutrality must be maintained across the membrane as this happens. Maintenance of neutrality can be accomplished in principle either by having a positively charged ion accompany HCO₃⁻ out of the cell or by having some other negatively charged ion enter the cell in exchange for the HCO₃⁻. Since the distribution of the major cations, Na⁺ and K⁺, is under strict control, it is the latter mechanism that is seen, and the ion that is exchanged for HCO₃⁻ is Cl⁻. Thus as HCO₃⁻ is formed in red cells during their passage through the capillary bed, it moves out into the plasma and Cl⁻ comes in to replace it. The increase in intracellular Cl⁻ is shown in the last line of Table 25.2. In the lungs, all events that occur in the peripheral capillary beds are reversed; HCO₃⁻ enters the erythrocytes to be converted to CO₂ for exhalation, and Cl⁻ returns to the plasma. The exchange of Cl⁻ and HCO₃⁻ between the plasma and the erythrocyte is called the **chloride shift** (Figure 25.12).


The intraerythrocytic buffering of H⁺ from carbon dioxide causes these cells to swell, giving venous blood a slightly (0.6%) higher hematocrit than arterial blood. (Hematocrit is the volume percent of red cells in the blood.) This occurs because the charge on the hemoglobin molecule becomes more positive with every H⁺ that binds to it. Each bound positive charge requires an accompanying negative charge to maintain neutrality. Thus as a result of buffering there is a net accumulation of HCO₃⁻ or Cl⁻ inside the erythrocyte.

Extrapulmonary capillaries



(a) Bicarbonate efflux from and chloride influx into erythrocytes in extrapulmonary tissues.

Pulmonary capillaries



(b) Chloride efflux from and bicarbonate influx into erythrocytes in pulmonary tissues.

FIGURE 25.12

Schematic representation of the chloride shift.

(a) In the capillaries of the extrapulmonary tissues, CO₂ produced by tissue metabolism is converted to HCO₃⁻ in the erythrocytes. This HCO₃⁻ exits the erythrocytes in exchange for Cl⁻. (b) In the capillaries of the lungs, HCO₃⁻ enters the erythrocytes in exchange for Cl⁻. Within the erythrocytes HCO₃⁻ is converted to CO₂. CO₂ subsequently diffuses out of the erythrocytes and is exhaled.




FIGURE 25.13

Interaction of H⁺, BPG, CO₂, and O₂ with hemoglobin.

This is a schematic, intended to denote the direction of the equilibrium, not the stoichiometry of the reaction.

An increase in the osmotic pressure of the intracellular fluid results from this increase in concentration of particles. As a consequence, water enters the cells, causing them to swell slightly. Typically, an arterial hematocrit might be 44.8 and a venous hematocrit 45.1, as shown in Table 25.2 by the line labeled "volume (cc L⁻¹ of blood)."

25.7 INTERRELATIONSHIPS AMONG HEMOGLOBIN, OXYGEN, CARBON DIOXIDE, HYDROGEN ION, AND 2,3-BISPHOSPHOGLYCERATE

By now it should be clear that multiple interrelationships of physiological significance exist among the ligands of hemoglobin. These interrelationships are summarized schematically in Figure 25.13. This equation shows that changes in the concentration of H⁺, BPG, or CO₂ have similar effects on O₂ binding. The equation will help you remember the effect of changes in any one of these variables upon hemoglobin's O₂ affinity.

BPG levels in the erythrocytes are controlled by product inhibition of its synthesis and by pH. Hypoxia results in increased levels of deoxyhemoglobin on a time-averaged basis. Since deoxyhemoglobin binds BPG more tightly, in hypoxia there is less free BPG to inhibit its own synthesis, and so BPG levels will rise due to increased synthesis. The effect of pH is that high pH increases BPG synthesis and low pH decreases BPG synthesis; this reflects the influence of pH on the activity of **BPG mutase**, the enzyme that catalyzes BPG formation. Since changes in BPG levels take many hours to become complete, this means that the immediate effect of a decrease in blood pH is to enhance oxygen delivery by the Bohr effect. If the acidosis is sustained (most causes of chronic metabolic acidosis are not associated with a need for enhanced oxygen delivery), diminished BPG synthesis leads to a decrease in intracellular BPG concentration, and hemoglobin's oxygen affinity returns toward normal (Figure 25.14). This system can respond appropriately to acute conditions, such as vigorous exercise, but when faced with a prolonged abnormality of pH, it readjusts to restore normal (and presumably optimal) oxygen delivery.




FIGURE 25.14

In chronic acidosis, BPG concentration decreases, returning hemoglobin's oxygen affinity toward normal.

This schematic diagram illustrates the rapid decrease in hemoglobin's oxygen affinity due to decreased pH. Lowering pH immediately lowers the activity of BPG mutase. In consequence, the concentration of BPG gradually diminishes as normal degradation proceeds. As BPG concentration diminishes, hemoglobin's oxygen affinity rises.

25.8 INTRODUCTION TO pH REGULATION

We have noted the large amount of H⁺ generated by carbon dioxide transport, and we considered the ways in which the blood pH is controlled. This is important because changes in blood pH will affect intracellular pH, which in turn may profoundly alter metabolism. Protein conformation is affected by pH, as is enzyme activity. In addition, the equilibria of important reactions that consume or generate hydrogen ions, such as any of the oxidation-reduction reactions involving pyridine nucleotides, are shifted by changes in pH.

Normal arterial plasma pH is 7.40 ± 0.05 ; the pH range compatible with life is about 6.8–7.8. Intracellular pH varies with cell type; that of the erythrocyte is nearly 7.2, but that of most other cells is lower, about 7.0. Values as low as 6.0 have been reported for skeletal muscle.

It is fortunate for both diagnosis and treatment of diseases that the acid-base status of intracellular fluid influences and is influenced by the acid-base status of the blood. Blood is readily available for analysis, and when alteration of body pH becomes necessary, intravenous administration of acidifying or alkalinizing agents is efficacious.

25.9 BUFFER SYSTEMS OF PLASMA, INTERSTITIAL FLUID, AND CELLS

Each body water compartment is defined spatially by one or more differentially permeable membranes. Each contains characteristic kinds and concentrations

on the DNA target. Rather, the contacts from one monomer combine with those of the second monomer to form a continuous interaction through the single binding site in the DNA.

3.5 HEMOGLOBIN AND MYOGLOBIN

Hemoglobins are globular proteins, present in high concentrations in red blood cells, that bind oxygen in the lungs and transport the oxygen in blood to tissues and cells around the capillary beds of the vascular system. Hemoglobins also transport carbon dioxide and protons from the tissues to the lungs. Hemoglobins carry and release nitric oxide (NO), a potent vasodilator and inhibitor of platelet aggregation (see p. 995). In this section the structural and molecular aspects of hemoglobin and myoglobin are described. The physiological roles of these proteins are discussed in Chapter 25.

Human Hemoglobin Occurs in Several Forms

A hemoglobin molecule consists of four polypeptide chains, two each of two different amino acid sequences. The major form of human adult hemoglobin, **HbA₁**, consists of two α chains and two β chains ($\alpha_2\beta_2$). The α polypeptide has 141 and the β polypeptide has 146 amino acids. Other forms of hemoglobin predominate in the blood of the human fetus and early embryo (Figure 3.30). The fetal form (**HbF**) contains the same α chains found in HbA₁, but a second type of chain (γ chain) occurs in the tetramer molecule and differs in amino acid sequence from that of the β chain of adult HbA₁ (Table 3.8). Additional forms appear in the first months after conception (embryonic) in which the α chains are substituted by *zeta* (ζ) chains of different amino acid sequence and the ϵ chains serve as the β chains. A minor form of adult hemoglobin, HbA₂, comprises about 2% of normal adult hemoglobin and contains two α chains and two chains designated delta (δ) (Table 3.8).

FIGURE 3.30
Changes in globin chain production during development.

Based on a figure in Nienhuis, A. W. and Mamiatis, T. In: G. Stamatoyannopoulos, A. W. Nienhuis, P. Leder, and P. W. Majerus (Eds.), *The Molecular Basis of Blood Diseases*. Philadelphia: Saunders, 1987, p. 68, in which reference of Weatherall, D. J., and Clegg, J. B., *The Thalassemia Syndromes*, 3rd ed. Oxford: Blackwell Scientific Publications, 1981, is acknowledged.




TABLE 3.8 Chains of Human Hemoglobin

Developmental Stage	Symbol	Chain Designations
Adult	HbA ₁	$\alpha_2\beta_2$
Adult	HbA ₂	$\alpha_2\delta_2$
Fetus	HbF	$\alpha_2\gamma_2$
Embryo	Hb Gower-1	$\zeta_2\epsilon_2$
Embryo	Hb Portland	$\zeta_2\gamma_2$

Myoglobin: A Single Polypeptide Chain with One O₂-Binding Site

Myoglobin (Mb) is an O₂-carrying protein that binds and releases O₂ with changes in the oxygen concentration in the sarcoplasm of skeletal muscle cells. In contrast to hemoglobin, which has four polypeptide chains and four O₂-binding sites, myoglobin contains only a single polypeptide chain and one O₂-binding site. Myoglobin is a model for what occurs when a single protomer molecule acts alone without the interactions exhibited among the four O₂-binding sites in the more complex tetramer molecule of hemoglobin.

A Heme Prosthetic Group Is at the Site of O₂ Binding

The four polypeptides of globin subunits in hemoglobin and the one of myoglobin each contain a heme prosthetic group. A **prosthetic group** is a nonpolypeptide moiety that forms a functional part of a protein. Without its prosthetic group, a protein is designated an **apoprotein**. With its prosthetic group it is a **holoprotein**.

Heme contains protoporphyrin IX (see Chapter 24) with an iron atom in its center (Figure 3.31). The iron atom is in the ferrous (2+ charge) oxidation state in functional hemoglobin and myoglobin. The ferrous atom in the heme can form five or six ligand bonds, depending on whether or not O₂ is bound to the molecule. Four bonds are to the pyrrole nitrogen atoms of the porphyrin. Since all pyrrole rings of porphyrin lie in a common plane, the four ligand bonds from the porphyrin to the iron atom will have a tendency to lie in the plane of the porphyrin ring. The fifth and the potentially sixth ligand bonds to the ferrous atom are directed along an axis perpendicular to the plane of the porphyrin ring (Figure 3.32). The fifth coordinate bond of the ferrous atom is to a nitrogen of a histidine imidazole. This is designated the **proximal histidine** in hemoglobin and myoglobin structures (Figures 3.32 and 3.33). O₂ forms a sixth coordinate bond to the ferrous atom when bound to hemoglobin. In this bonded position the O₂ is placed between the ferrous atom to which it is liganded and a second histidine imidazole, designated the **distal histidine**. In deoxyhemoglobin, the sixth coordination position of the ferrous atom is unoccupied.




FIGURE 3.31
Structure of heme.




FIGURE 3.32
Ligand bonds to ferrous atom in oxyhemoglobin.




FIGURE 3.33
Secondary and tertiary structure characteristics of chains of hemoglobin.

Proximal His F8, distal His E7, and Val E11 side chains are shown. Other amino acids of polypeptide chain are represented by α -carbon positions only; the letters M, V, and P refer to the methyl, vinyl, and propionate side chains of the heme.

Reprinted with permission from Perutz, M. Br. Med. Bull. 32:195, 1976.

The porphyrin part of the heme is positioned within a hydrophobic pocket of each globin subunit. In the heme pocket X-ray diffraction studies show that approximately 80 interactions are provided by approximately 18 residues to the heme. Most of these noncovalent interactions are between apolar side chains of amino acids and the apolar regions of the porphyrin. As discussed in Chapter 2, the driving force for these interactions is the expulsion of water of solvation on association of the hydrophobic heme with the apolar amino acid side chains in the heme pocket. In myoglobin additional noncovalent interactions are made between the negatively charged propionate groups of the heme and positively charged arginine and histidine side chains of the protein. However, in hemoglobin chains a difference in the amino acid sequence in this region of the heme-binding site leads to stabilization of the porphyrin propionates by interaction with an uncharged histidine imidazole and with water molecules of solvent toward the outer surface of the molecule.

X-Ray Crystallography Has Assisted in Defining the Structure of Hemoglobin and Myoglobin

The structure of deoxy and oxy forms of hemoglobin and myoglobin have been resolved by X-ray crystallography. In fact, sperm whale myoglobin was the first globular protein whose full three-dimensional structure was determined by this technique. This was followed by the X-ray structure of the more complex horse hemoglobin molecule. These structures show that each globin polypeptide in the hemoglobins and the single subunit of myoglobin are composed of multiple α -helical regions connected by turns of the polypeptide chain that allow the protein to fold into a spheroidal shape (Figure 3.33). The mechanism of cooperative associations of O_2 , discussed below, is based on the X-ray structures of oxyhemoglobin, deoxyhemoglobin, and a variety of hemoglobin derivatives.

Primary, Secondary, and Tertiary Structures of Myoglobin and the Individual Hemoglobin Chains

The amino acid sequences of the polypeptide chain of myoglobin of 23 different animal species have been determined. All myoglobins contain 153 amino acids in their polypeptide chains, of which 83 are invariant. Only 15 of these invariant residues in the myoglobin sequence are identical to the invariant residues of the sequenced mammalian globins of hemoglobin. However, the changes are, in the great majority of cases, conservative and preserve the general physical properties of the residues (Table 3.9). Since myoglobin is active as a monomer, many of its surface positions interact with water and prevent another molecule of myoglobin from associating. In contrast, surface residues of the individual subunits in hemoglobin are designed to provide hydrogen bonds and nonpolar contacts with other subunits in the hemoglobin quaternary structure. Proximal and distal histidines are preserved in the sequences of all the polypeptide chains. Other invariant residues are in the hydrophobic heme pocket and form essential nonpolar contacts with the heme that stabilize the heme-protein complex.

While there is surprising variability in amino acid sequences among the different polypeptide chains, to a first approximation the secondary and tertiary structures of each of the subunits of hemoglobin and myoglobin are almost identical (Figure 3.34). Significant differences in physiological properties between α , β , γ , and δ chains of hemoglobins and the polypeptide chain of myoglobin are due to rather small specific changes in their structures. The similarity in tertiary structure, resulting from widely varied amino acid sequences, shows that the same tertiary structure for a protein can be arrived at by many different sequences.

TABLE 3.9 Amino Acid Sequences of Human Hemoglobin Chains and of Sperm Whale Myoglobin^a

	NA 1	2	3	A 1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	A 16	AB 1	B 1	2	3	4	5	6		
MYOGLOBIN	Val	...	Leu	Ser	Glu	Gly	Glu	Trp	Gln	Leu	Val	Leu	His	Val	Trp	Ala	Lys	Val	Glu	Ala	Asp	Val	Ala	Gly	His	Gly		
HEMOGLOBIN	Horse	α	Val	...	Leu	Ser	Ala	Ala	Asp	Lys	Thr	Asn	Val	Lys	Ala	Ala	Trp	Ser	Gly	Gly	His	Ala	Gly	Glu	Tyr	Gly		
		β	Val	Gln	Leu	Ser	Gly	Glu	Glu	Lys	Ala	Ala	Val	Leu	Ala	Leu	Trp	Asp	Lys	Val	Asn	Glu	Glu	Val	Gly	
		α	Val	...	Leu	Ser	Pro	Ala	Asp	Lys	Thr	Asn	Val	Lys	Ala	Ala	Trp	Gly	Lys	Val	Gly	Ala	His	Ala	Gly	Glu	Tyr	Gly
		β	Val	His	Leu	Thr	Pro	Glu	Glu	Lys	Ser	Ala	Val	Thr	Ala	Leu	Trp	Gly	Lys	Val	Asn	Val	Asp	Glu	Val	Gly
HEMOGLOBIN	Human	α	Gly	His	Phe	Thr	Glu	Glu	Asp	Lys	Ala	Thr	Ile	Thr	Ser	Leu	Trp	Gly	Lys	Val	Asn	Val	Glu	Asp	Ala	Gly
		β	Val	His	Leu	Thr	Pro	Glu	Glu	Lys	Thr	Ala	Val	Asn	Ala	Leu	Trp	Gly	Lys	Val	Asn	Val	Asp	Ala	Val	Gly
		γ	Gly	His	Phe	Thr	Glu	Glu	Asp	Lys	Ala	Thr	Ile	Thr	Ser	Leu	Trp	Gly	Lys	Val	Asn	Val	Glu	Asp	Ala	Gly
		δ	Val	His	Leu	Thr	Pro	Glu	Glu	Lys	Thr	Ala	Val	Asn	Ala	Leu	Trp	Gly	Lys	Val	Asn	Val	Asp	Ala	Val	Gly
	7	8	9	10	11	12	13	14	15	16	C 1	2	3	4	5	6	7	CD 1	2	3	4	5	6	7	8	D 1		
MYOGLOBIN	Gln	Asp	Ile	Leu	Ile	Arg	Leu	Phe	Lys	Ser	His	Pro	Glu	Thr	Leu	Glu	Lys	Phe	Asp	Arg	Phe	Lys	His	Leu	Lys	Thr		
HEMOGLOBIN	Horse	α	Ala	Glu	Ala	Leu	Glu	Arg	Met	Phe	Leu	Gly	Phe	Pro	Thr	Lys	Thr	Lys	Phe	Pro	His	Phe	Gly	Asp	His	
		β	Gly	Glu	Ala	Leu	Gly	Arg	Leu	Leu	Val	Val	Tyr	Pro	Trp	Thr	Gln	Arg	Phe	Phe	Asp	His	Phe	Gly	Asp	
		α	Ala	Glu	Ala	Leu	Glu	Arg	Met	Phe	Leu	Ser	Phe	Pro	Thr	Thr	Lys	Thr	Lys	Phe	Pro	His	Phe	Gly	Asp	
		β	Gly	Glu	Ala	Leu	Gly	Arg	Leu	Leu	Val	Val	Tyr	Pro	Trp	Thr	Gln	Arg	Phe	Phe	Glu	Ser	Phe	Gly	Asp	Leu	Ser	Thr
HEMOGLOBIN	Human	α	Ala	Glu	Ala	Leu	Glu	Arg	Met	Phe	Leu	Ser	Phe	Pro	Thr	Thr	Lys	Thr	Lys	Phe	Pro	His	Phe	Gly	Asp	
		β	Gly	Glu	Ala	Leu	Gly	Arg	Leu	Leu	Val	Val	Tyr	Pro	Trp	Thr	Gln	Arg	Phe	Phe	Glu	Ser	Phe	Gly	Asp	Leu	Ser	
		γ	Gly	Glu	Thr	Leu	Gly	Arg	Leu	Leu	Val	Val	Tyr	Pro	Trp	Thr	Gln	Arg	Phe	Phe	Asp	Ser	Phe	Gly	Asn	Leu	Ser	
		δ	Gly	Glu	Ala	Leu	Gly	Arg	Leu	Leu	Val	Val	Tyr	Pro	Trp	Thr	Gln	Arg	Phe	Phe	Glu	Ser	Phe	Gly	Asn	Leu	Ser	
	2	3	4	5	6	7	E 1	2	3	4	5	6	7	8	9	10	11	12	13	14	E 15	16	17	18	19	20		
MYOGLOBIN	Glu	Ala	Glu	Met	Lys	Ala	Ser	Glu	Asp	Leu	Lys	Lys	His	Gly	Val	Thr	Val	Leu	Thr	Ala	Leu	Gly	Ala	Ile	Leu	Lys		
HEMOGLOBIN	Horse	α	
		β	Pro	Asp	Ala	Val	Met	Gly	Asn	Pro	Lys	Val	Val	Lys	Ala	His	Gly	Lys	Val	Leu	His	Ser	Phe	Glu	Gly	Val	His	
		α
		β	Pro	Asp	Ala	Val	Met	Gly	Asn	Pro	Lys	Val	Val	Val	Lys	Ala	His	Gly	Lys	Val	Leu	Gly	Ala	Phe	Ser	Asp	Gly	Ile
HEMOGLOBIN	Human	α	
		β	Pro	Asp	Ala	Val	Met	Gly	Asn	Pro	Lys	Val	Val	Val	Lys	Ala	His	Gly	Lys	Val	Leu	Gly	Ala	Phe	Ser	Asp	Gly	Ile
		γ	Ala	Der	Ala	Ile	Met	Gly	Asn	Pro	Lys	Val	Lys	Val	Lys	Ala	His	Gly	Lys	Val	Leu	Thr	Ser	Leu	Gly	Asp	Ala	Ile
		δ	Pro	Asp	Ala	Val	Met	Gly	Asn	Pro	Lys	Val	Lys	Val	Lys	Ala	His	Gly	Lys	Val	Leu	Gly	Ala	Phe	Ser	Asp	Gly	Leu
	EF 1	2	3	4	5	6	7	8	F 1	2	3	4	5	6	7	8	9	FG 1	2	3	4	5	G 1	2	3	4		
MYOGLOBIN	Lys	Lys	Gly	His	His	Glu	Ala	Glu	Leu	Lys	Pro	Leu	Ala	Gln	Ser	His	Ala	Thr	Lys	His	Lys	Ile	Pro	Ile	Lys	Tyr		
HEMOGLOBIN	Horse	α	His	Lys	Asp	Asp	Leu	Pro	Gly	Ala	Leu	Ser	Asp	Lys	Asn	Leu	His	Ala	His	Lys	Leu	Arg	Val	Asp	Pro	Val	Asn	
		β	His	Leu	Asp	Asn	Leu	Lys	Gly	Thr	Phe	Ala	Ala	Leu	Ser	Glu	Leu	His	Cys	Asp	Lys	Leu	His	Val	Asp	Pro	Glu	
		α	His	Val	Asp	Asp	Met	Pro	Asn	Ala	Leu	Ser	Ala	Leu	Ser	Asp	Leu	His	Ala	His	Lys	Leu	Arg	Val	Asp	Pro	Val	
		β	His	Leu	Asp	Asn	Leu	Lys	Gly	Thr	Phe	Ala	Thr	Leu	Ser	Glu	Leu	His	Cys	Asp	Lys	Leu	His	Val	Asp	Pro	Glu	
HEMOGLOBIN	Human	α	His	Val	Asp	Asp	Met	Pro	Asn	Ala	Leu	Ser	Ala	Leu	Ser	Asp	Leu	His	Ala	His	Lys	Leu	Arg	Val	Asp	Pro	Val	
		β	His	Leu	Asp	Asn	Leu	Lys	Gly	Thr	Phe	Ala	Thr	Leu	Ser	Glu	Leu	His	Cys	Asp	Lys	Leu	His	Val	Asp	Pro	Glu	
		γ	His	Leu	Asp	Asn	Leu	Lys	Gly	Thr	Phe	Ala	Gln	Leu	Ser	Glu	Leu	His	Cys	Asp	Lys	Leu	His	Val	Asp	Pro	Glu	
		δ	His	Leu	Asp	Asn	Leu	Lys	Gly	Thr	Phe	Ser	Gln	Leu	Ser	Glu	Leu	His	Cys	Asp	Lys	Leu	His	Val	Asp	Pro	Glu	
	5	6	7	8	G 9	10	11	12	13	14	15	16	17	18	19	GH 1	2	3	4	5	6	H 1	2	H 3	4	5		
MYOGLOBIN	Leu	Glu	Phe	Ile	Ser	Glu	Ala	Ile	Ile	His	Val	Leu	His	Ser	Arg	His	Pro	Gly	Asn	Phe	Gly	Ala	Asp	Ala	Gln	Gly		
HEMOGLOBIN	Horse	α	Phe	Lys	Leu	Leu	Ser	His	Cys	Leu	Leu	Ser	Thr	Leu	Ala	Val	His	Leu	Pro	Asn	Asp	Phe	Thr	Pro	Ala	Val	His	
		β	Phe	Arg	Leu	Leu	Gly	Asn	Val	Leu	Ala	Val	Val	Ala	Arg	His	Phe	Gly	Lys	Asp	Phe	Thr	Pro	Glu	Leu	Gln	Ala	
		α	Phe	Lys	Leu	Leu	Ser	His	Cys	Leu	Leu	Val	Thr	Leu	Ala	Ala	His	Leu	Pro	Ala	Glu	phe	Thr	Pro	Ala	Val	His	
		β	Phe	Srg	Leu	Leu	Gly	Asn	Val	Leu	Val	Cys	Val	Leu	Ala	His	Phe	Gly	Lys	Glu	Phe	Thr	Pro	Pro	Val	Gln	Ala	
HEMOGLOBIN	Human	α	Phe	Lys	Leu	Leu	Gly	Asn	Val	Leu	Val	Thr	Val	Leu	Ala	His	His	Phe	Gly	Lys	Glu	Phe	Thr	Pro	Val	Gln		
		β	Phe	Srg	Leu	Leu	Gly	Asn	Val	Leu	Val	Cys	Val	Leu	Ala	His	Phe	Gly	Lys	Glu	Phe	Thr	Pro	Pro	Val	Gln		
		γ	Phe	Lys	Leu	Leu	Gly	Asn	Val	Leu	Val	Thr	Val	Leu	Ala	His	Phe	Gly	Lys	Glu	Phe	Thr	Pro	Glu	Val	Gln		
		δ	Phe	Arg	Leu	Leu	Gly	Asn	Val	Leu	Val	Cys	Val	Leu	Ala	Arg	Asn	Phe	Gly	Lys	Glu	Phe	Thr	Pro	Gln	Met		
	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	H 21	22	23	2	HC 1	2	3	4	5				
MYOGLOBIN	Ala	Met	Asn	Lys	Ala	Leu	Glu	Leu	Phe	Arg	Lys	Asp	Ile	Ala	Ala	Lys	Tyr	Lys	Glu	Leu	Gly	Tyr	Gln	Gly				
HEMOGLOBIN	Horse	α	Ser	Leu	Asp	Lys	Phe	Leu	Ser	Val	Ser	Thr	Val	Leu	Thr	Ser	Lys	Tyr	Arg									
		β	Ser	Tyr	Gln	Lys	Val	Val	Ala	Gly	Val	Ala	Asn	Ala	Leu	Ala	His	Lys	Tyr	His								
		α	Ser	Leu	Asp	Lys	Phe	Leu	Ala	Ser	Val	Ser	Thr	Val	Leu	Thr	Ser	Lys	Tyr	Arg								
		β	Ala	Tyr	Gln	Lys	Val	Val	Ala	Gly	Val	Ala	Asn	Ala	Leu	Ala	His	Lys	Tyr	His								
HEMOGLOBIN	Human	α	Ser	Trp	Gln	Lys	Met	Val	Thr	Gly	Val	Ala	Ser	Ala	Ser	Ser	Arg	Tyr	His									
		β	Ala	Tyr	Gln	Lys	Val	Val	Ala	Gly	Val	Ala	Asn	Ala	Leu	Ala	His	Lys	Tyr	His								
		γ	Ser	Trp	Gln	Lys	Met	Val	Thr	Gly	Val	Ala	Ser	Ala	Leu	Ser	Ser	Arg	Tyr	His								
		δ	Ala	Tyr	Gln	Lys	Val	Val	Ala	Gly	Val	Ala	Asn	Ala	Leu	Ala	His	Lys	Tyr	His								

Source: Based on diagram in Dickerson, R. E., and Geis, I. *The Structure and Function of Proteins*. New York: Harper & Row, 1969, p. 52.

^a Residues that are identical are enclosed in box. A, B, C, . . . designate different helices of tertiary structure (see text).

Approximately 70% of the residues participate in the α -helical secondary structures generating seven helical segments in the α chain and eight in the β chain. These latter eight helical regions are commonly lettered A–H, starting from the first (A) helix at the

$$Y = \frac{\text{number of binding sites occupied}}{\text{total number of binding sites in solution}} \quad (3.4)$$

$$Y = \frac{[\text{MbO}_2]}{[\text{Mb}] + [\text{MbO}_2]} \quad (3.5)$$

$$Y = \frac{p\text{O}_2}{P_{50} + p\text{O}_2} \quad (3.6)$$

A plot of Eq. 3.6 of Y versus $p\text{O}_2$ generates an oxygen-saturation curve for myoglobin in the form of a rectangular hyperbola (Figure 3.35).

A simple algebraic manipulation of Eq. 3.6 leads to Eq. 3.7. Taking the logarithm of both sides of Eq. 3.7 results in Eq. 3.8, the **Hill equation**. A plot of $\log \left(\frac{Y}{1 - Y} \right)$ versus $\log p\text{O}_2$, according to Eq. 3.8, yields a straight line with a slope equal to 1 for myoglobin (Figure 3.36). This is the Hill plot, and the slope (n_H) is the **Hill coefficient** (see Eq. 3.9).

$$\frac{Y}{1 - Y} = \frac{p\text{O}_2}{P_{50}} \quad (3.7)$$

$$\log \frac{Y}{1 - Y} = \log p\text{O}_2 - \log P_{50} \quad (3.8)$$

Binding of O₂ to Hemoglobin Involves Cooperativity Between the Hemoglobin Subunits

Whereas myoglobin has a single O₂-binding site per molecule, hemoglobins, with four monomeric subunits, have four heme-binding sites for O₂. Binding of the four O₂ molecules in hemoglobin is found to be **positively cooperative**, so that the binding of the first O₂ to deoxyhemoglobin facilitates the binding of O₂ to the other subunits in the molecule. Conversely, dissociation of the first O₂ from fully oxygenated hemoglobin, Hb(O₂)₄, will make the dissociation of O₂ from the other subunits of the tetramer easier.

Because of cooperativity in oxygen association and dissociation, the oxygen saturation curve for hemoglobin differs from that for myoglobin. A plot of Y versus $p\text{O}_2$ for hemoglobin is a sigmoidal line, indicating cooperativity in oxygen association (Figure 3.35). A plot of the Hill equation (Eq. 3.9) gives a value of the slope (n_H) equal to 2.8 (Figure 3.36).

$$\log \frac{Y}{1 - Y} = n_H \log p\text{O}_2 - \text{constant} \quad (3.9)$$

The meaning of the Hill coefficient to cooperative O₂ association can be evaluated quantitatively as presented in Table 3.10. A parameter known as the **cooperativity index**, R_x , is calculated, which shows the ratio of $p\text{O}_2$ required to change Y from a value of $Y = 0.1$ (10% of sites filled) to a value of $Y = 0.9$ (90% of sites filled) for designated Hill coefficient values found experimentally. For myoglobin, $n_H = 1$, and an 81-fold change in oxygen concentration is required to change from $Y = 0.1$ to $Y = 0.9$. For hemoglobin, where positive cooperativity is observed, $n_H = 2.8$ and only a 4.8-fold change in oxygen concentration is required to change the fractional saturation from 0.1 to 0.9.

The Molecular Mechanism of Cooperativity in O₂ Binding

X-ray diffraction data on deoxyhemoglobin show that the ferrous atoms actually sit out of the plane of their porphyrins by about 0.4–0.6 Å. This is thought to occur because of two factors. The electronic configuration of the five-coordinated ferrous atom in deoxyhemoglobin has a slightly larger radius than the distance from the center of the porphyrin to each of the pyrrole nitrogen atoms.




FIGURE 3.35 Oxygen-binding curves for myoglobin and hemoglobin.




FIGURE 3.36 Hill plots for myoglobin and hemoglobin HbA₁.

TABLE 3.10 Relationship Between Hill Coefficient (n_H) and Cooperativity Index (R_x)

n_H	R_x	Observation
0.5	6560	Negative substrate cooperativity
0.6	1520	
0.7	533	
0.8	243	
0.9	132	
1.0	81.0	Noncooperativity
1.5	18.7	Positive substrate cooperativity
2.0	9.0	
2.8	4.8	
3.5	3.5	
6.0	2.1	
10.0	1.6	
20.0	1.3	

Source: Based on Table 7.1 in Cornish-Bowden, A. *Principles of Enzyme Kinetics*. London: Butterworths Scientific Publishers, 1976.

Accordingly, the iron can be placed in the center of the porphyrin only with some distortion of the porphyrin conformation. Probably a more important consideration is that if the iron atom sits in the plane of the porphyrin, the proximal His F8 imidazole will interact unfavorably with atoms of the porphyrin. The strength of this unfavorable steric interaction is due, in part, to conformational constraints on the His F8 and the porphyrin in the deoxyhemoglobin conformation that forces the approach of the His F8 toward the porphyrin to a particular path (Figure 3.37). These constraints become less significant in the oxy conformation of hemoglobin.

The conformation with the iron atom out of the plane of the porphyrin is unstrained and energetically favored for the five-coordinate ferrous atom. When O_2 binds the sixth coordinate position of the iron, however, this conformation becomes strained. A more energetically favorable conformation for the O_2 liganded iron is one in which the iron atom is within the plane of the porphyrin structure.

On binding of O_2 to a ferrous atom the favorable free energy of bond formation overcomes the repulsive interaction between His F8 and porphyrin, and the ferrous atom moves into the plane of the porphyrin ring. This is the most thermodynamically stable position for the now six-bonded iron atom; one axial ligand is on either side of the plane of the porphyrin ring, and the steric repulsion of one of the axial ligands with the porphyrin is balanced by the repulsion of the second axial ligand on the opposite side when the ferrous atom is in the center. If the iron atom is displaced from the center, the steric interactions of the two axial ligands with the porphyrin in the deoxy conformation are unbalanced, and the stability of the unbalanced structure will be lower than that of the equidistant conformation. Also, the radius of the iron atom with six ligands is reduced so that it can just fit into the center of the porphyrin without distortion of the porphyrin conformation.

Since steric repulsion between porphyrin and His F8 in the deoxy conformation must be overcome on O_2 association, binding of the first O_2 is characterized by a relatively low affinity constant. However, when O_2 association occurs to the first heme in deoxyhemoglobin, the change in position of the iron atom from above the plane of the porphyrin into the center of the porphyrin triggers




FIGURE 3.37
Steric hindrance between proximal histidine and porphyrin in deoxyhemoglobin.

From Perutz, *M. Sci. Am.*, 239:92, 1978 Copyright © 1978 by Scientific American, Inc. All rights reserved.

a conformational change in the whole molecule. The change in conformation results in a greater affinity of O_2 to the other heme sites after the first O_2 has bound.

The conformation of deoxyhemoglobin is stabilized by noncovalent interactions of the quaternary structure at the interface between α and β subunits in which the FG corner of one subunit noncovalently binds to the C helix of the adjacent subunit (Figure 3.38). In addition, ionic interactions stabilize the deoxy





FIGURE 3.38
Quaternary structure of hemoglobin.
 (a) $\alpha_1\beta_2$ interface contacts between FG corners and C helix are shown. (b) Cylinder representation of α_1 and β_2 subunits in hemoglobin molecule showing α_1 and β_2 interface contacts between FG corner and C helix, viewed from opposite side of x - y plane from (a).
 (a) Reprinted with permission from Dickerson, R. E., and Geis, I. *The Structure and Action of Proteins*. Menlo Park, CA: Benjamin, Inc., 1969, p. 56.
 (b) Reprinted with permission from Baldwin, J., and Chothia, C. J. *Mol. Biol.* 129:175, 1979. Copyright © 1979 by Academic Press, Inc. (London) Ltd.

FIGURE 3.39
Salt bridges between subunits in deoxyhemoglobin.

Im⁺ is imidazolium; Gua⁺ is guanidinium; starred residues account for approximately 60% of alkaline Bohr effect.

Redrawn from Perutz, M. Br. Med. Bull. 32:195, 1976.



conformation of the protein (Figure 3.39). These interactions of the deoxy conformation are now destabilized on the binding of O₂ to one of the heme subunits of a deoxyhemoglobin molecule. The binding of O₂ pulls the Fe²⁺ atom into the porphyrin plane and moves the His F8 toward the porphyrin and with it the F helix of which the His F8 is a part. Movement of the F helix, in turn, moves the FG corner of its subunit, destabilizing the FG noncovalent interaction with the C helix of the adjacent subunit at an $\alpha_2\beta_2$ or $\alpha_2\beta_1$ subunit interface (Figures 3.38 and 3.40).




FIGURE 3.40
Stick and space-filling diagrams drawn by computer graphics showing movements of residues in heme environment on transition from deoxyhemoglobin to oxyhemoglobin.

(a) Black line outlines position of polypeptide chain and His F8 in carbon monoxide hemoglobin, a model for oxyhemoglobin. Red line outlines the same for deoxyhemoglobin. Position of iron atom shown by circle. Movements are for an α subunit. (b) Similar movements in a β subunit using space-filling diagram shown. Residue labels centered in density for the deoxyconformation.

Redrawn with permission from Baldwin, J., and Chotbia, C. J. Mol. Biol. 129:175, 1979. Copyright © 1979 by Academic Press, Inc. (London) Ltd.


The FG to C intersubunit contacts act as a "switch," because they exist in two different arrangements with different modes of contact between the FG corner of one subunit and the C helix of the adjacent subunit. The switch in noncovalent interactions between the two positions involves a relative movement of FG and C in adjacent subunits of about 6 Å. In the second position of the "switch," the tertiary conformation of the subunits participating in the FG to C intersubunit contact is less constrained and the adjacent subunit changes to a new tertiary conformation (oxy conformation) even without O₂ bound. This oxy conformation allows the His F8 residues to approach their porphyrins on O₂ association with a less significant steric repulsion than in the deoxy conformation (Figure 3.40). Thus an O₂ molecule binds to the empty hemes in the less constrained oxy conformation more easily than to a subunit conformation held by the quaternary interactions in the deoxy conformation.

In addition, Val E11 in the deoxy conformation of β subunits is at the entrance to the O₂-binding site, where it sterically impedes O₂ association to heme (see Figure 3.33). In the oxy conformation the heme in β subunits moves approximately 1.5 Å further into the heme-binding site, changing the geometric relationship of the O₂-binding site to the Val E11 side chain, so that the Val E11 no longer sterically interferes with O₂ binding. This is an important additional factor that increases affinity of O₂ for the oxy conformation of the β chain over that for the deoxy conformation.

The deoxy conformation of hemoglobin is referred to as the "tense" or **T conformational state**. The oxyhemoglobin conformational form is referred to as the "relaxed" or **R conformational state**. The allosteric mechanism shows how initial binding of the oxygen to one of the heme subunits of the tetrameric molecule pushes the molecular conformation from the T to R conformational state. The affinity constant of O₂ is greater for the R state hemes than the T state by a factor of 150–300, depending on the solution conditions.

The Bohr Effect Involves Dissociation of a Proton on Binding of Oxygen

The equilibrium expression for oxygen association to hemoglobin includes a term that indicates participation of H⁺ in the equilibrium.



Equation 3.10 shows that the R form is more acidic, and the H⁺ dissociate when hemoglobin is changed to the R form. The equivalents of H⁺ that dissociate per mole of hemoglobin depends on the pH of the solution and the concentration of other factors that can bind to hemoglobin, such as Cl⁻ and bisphosphoglycerate (see Chapter 25). At pH 7.4, the value of *x* may vary from 1.8 to 2.8, depending on the solution conditions. This production of H⁺ at an alkaline pH (pH > 6), when deoxyhemoglobin is transformed to oxyhemoglobin, is known as the alkaline **Bohr effect**.

The H⁺ are derived from the partial dissociation of acid residues with p*K*'_a values within 1.5 pH units of the solution pH, which change from a higher to lower p*K*'_a, on the change of the T to R conformation. For example, the HC3 His 146(β) in the deoxy (T) conformation is predominantly in its imidazolium form (positively charged acid form), which is stabilized by a favorable interaction with the negatively charged side chain of the FG1 Asp 94(β) (Figure 3.39). This ion pair makes it more difficult to remove the imidazolium proton and thus raises the p*K*'_a of the imidazolium to a higher value than normally found for a free imidazolium ion in solution, where a stabilization by a proximal negatively charged group does not normally occur. However, on conversion of the protein to the R conformation, the strength of this ionic interaction is broken and the imidazolium assumes a lower p*K*'_a. The decrease in p*K*'_a of histidine at blood pH results in conversion of some of its acid form to its conjugate base (imidazole) form, with dissociation of H⁺ that forms a part of the Bohr effect. Breakage of

this ion pair with release of protons accounts for 50% of the H^+ released on conversion to the R conformation. Other acid groups in the protein contribute the additional H^+ due to analogous decreases in their pK'_a values on changing from the T to R conformation.

The equilibrium involving hydrogen ions produced by the Bohr effect has important physiological consequences. Cells metabolizing at high rates, with high requirements for molecular oxygen, produce carbonic acid and lactic acid, which act to increase the hydrogen ion concentration in the cell's environment. As the increase in hydrogen ion concentration forces the equilibrium of Eq. 3.10 to the left, from the higher O_2 affinity conformation (R) to the lower affinity conformation (T), an increased amount of oxygen is dissociated from the hemoglobin molecule.

BIBLIOGRAPHY

Immunoglobulins

- Alzari, P. M., Lascombe, M.-B., and Poljak, R. J. Structure of antibodies. *Annu. Rev. Immunol.* 6:555, 1988.
- Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M., Smith-Gill, S. J., Air, G., Sheriff, S., Padlan, E. A., Davies, D., Tulip, W. R., Colman, P. M., Spinelli, S., Alzari, P. M., and Poljak, R. J. Conformations of immunoglobulin hyper-variable regions. *Nature* 342:877, 1989.
- Davies, D. R., Padlan, E. A., and Sheriff, S. Antibody-antigen complexes. *Acc. Chem. Res.* 26:421, 1993.
- Guddat, L. W., Shan, L., Fan, Z.-C., Andersen, K. N., Rosauer, R., Linthicum, D. S., and Edmundson, A. B. Intramolecular signaling upon complexation. *FASEB J.* 9:101, 1995.
- Hunkapiller, T., and Hood, L. Diversity of the immunoglobulin gene superfamily. *Adv. Immunol.* 44:1, 1989.
- Padlan, E. A. Anatomy of the antibody molecule. *Mol. Immunol.* 31:169, 1994.
- Rini, J. M., Schultze-Gahmen, U., Wilson, I. A. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. *Science* 255:959, 1992.
- Stanfield, R. L., Takimoto-Kaminmura, M., Rini, J. M., Profy, A. T., and Wilson, I. A. Major antigen-induced domain rearrangements in an antibody. *Structure* 1:83, 1993.

Serine Proteases

- Birk, Y. Proteinase inhibitors. In: A. Neuberger and K. Brocklehurst (Eds.), *Hydrolytic Enzymes*. Amsterdam: Elsevier, 1987, p. 257.
- Dufton, M. J. Could domain movements be involved in the mechanism of trypsin-like serine proteases? *FEBS Lett.* 271:9, 1990.
- Greer, J. Comparative modeling methods: application to the family of the mammalian serine proteases. *Proteins* 7:317, 1990.
- Liebman, M. N. Structural organization in the serine proteases. *Enzyme* 36:115, 1986.
- Neurath, H. Proteolytic processing and physiological regulation. *Trends Biochem. Sci.* 14:268, 1989.
- Perona, J. J., and Craik, C. S. Structural basis of substrate specificity in the serine proteases. *Protein Sci.* 4:337, 1995.
- Polgar, L. Structure and function of serine proteases. In: A. Neuberger and K. Brocklehurst (Eds.), *Hydrolytic Enzymes*, series in *New Comprehensive Biochemistry*, Vol. 16. Amsterdam: Elsevier, 1987, p. 159.
- Zwaal, R. F. A., and Hemker, H. C. (Eds.). *Blood Coagulation*, series in *New Comprehensive Biochemistry*, Vol. 13. Amsterdam: Elsevier, 1986.

DNA-Binding Proteins

- Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. Structure and mechanism of DNA topoisomerase II. *Nature* 379:225, 1996.
- Cho, Y., Gorina, S., Jeffrey, P. D., Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. *Science* 265:346, 1994.

- Ellenberger, T. E., Brandl, C. J., Struhl, K., and Harrison, S. C. The GCN4 basic region leucine zipper binds DNA as a dimer of uninterrupted α helices: crystal structure of the protein-DNA complex. *Cell* 71:1223, 1992.
- Ghosh, G., Van Duyne, G., Ghosh, S., and Sigler, P. B. Structure of NF- κ B p50 homodimer bound to a κ B site. *Nature* 373:303, 1995.
- Landschulz, W. H., Johnson, P. F., and McKnight, S. L. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. *Science* 240:1759, 1988.
- Lee, M. S., Gippert, G. P., Soman, K. V., Case, D. A., and Wright, P. E. Three-dimensional solution structure of a single zinc finger DNA-binding domain. *Science* 245:635, 1989.
- Lewis, M., Chang, G., Horton, N. C., Kercher, M. A., Pace, H. C., Schumacher, M. A., Brennan, R. G., and Lu, P. Crystal structure of the lactose operon repressor and its complexes with DNA and inducer. *Science* 271:1247, 1996.
- Müller, C. W., Rey, F. A., Sodeoka, M., Verdine, G. L., and Harrison, S. C. Structure of the NF- κ B p50 homodimer bound to DNA. *Nature* 373:311, 1995.
- Nikolov, D. B., Chen, H., Halay, E. D., Usheva, A. A., Hisatake, K., Lee, D. K., Roeder, R. G., and Burley, S. K. Crystal structure of a TFIIB-TBP-TATA-element ternary complex. *Nature* 377:119, 1995.
- Pavletich, N. P., and Pabo, C. O. Zinc finger-DNA recognition: crystal structure of a Zif-268-DNA complex at 2.1 Å. *Science* 252:809, 1991.
- Pellegrini, L., Tan, S., and Richmond, T. J. Structure of serum response factor core bound to DNA. *Nature* 376:490, 1995.

Hemoglobin

- Baldwin, J., and Chothia, C. Haemoglobin: the structural changes related to ligand binding and its allosteric mechanism. *J. Mol. Biol.* 129:175, 1979.
- Busch, M. R., Mace, J. E., Ho, N. T., and Ho, C. Roles of the β -146 histidyl residue in the molecular basis of the Bohr effect of hemoglobin: a protein nuclear magnetic resonance study. *Biochemistry* 30:1865, 1991.
- Dickerson, R. E., and Geis, I. *Hemoglobin: Structure, Function, Evolution and Pathology*. Menlo Park, CA: Benjamin-Cummings, 1983.
- Ho, C. Proton nuclear magnetic resonance studies on hemoglobin: cooperative interactions and partially ligated intermediates. *Adv. Protein Chem.* 43:154, 1992.
- Jayaraman, V., Rodgers, K. R., Mukerji, I., and Spiro, T. G. Hemoglobin allostery: resonance Raman spectroscopy of kinetic intermediates. *Science* 269:1843, 1995.
- Jia, L., Bonaventura, C., Bonaventura, J., and Stamler, J. S. S-Nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. *Nature* 380:221, 1996.
- Mathews, A. J., Rohlfs, R. J., Olson, J. S., Tame, J., Renaud, J. P., and Nagai, K. The effects of E7 and E11 mutations on the kinetics of ligand binding to R state human hemoglobin. *J. Biol. Chem.* 264:16573, 1989.

